Basetra

Basetra Medical Technology Co., Ltd. is a high-tech service company headquartered in Shanghai, China, that was established on February 28, 2014. The legal representative is Chen Chen. The company specializes in applying next-generation technologies to life sciences and human health, with a particular focus on prenatal testing.

Basetra's core technological competencies are in rare cell capture, single-cell diagnostics, and whole-genome sequencing analysis. The company has developed the Mycyte™, a fully automatic fluorescent-staining circulating rare cell capture instrument. This product utilizes MEMS microfluidic technology to efficiently isolate rare cells from biological fluid samples, such as circulating tumor cells (CTCs), stem cells, and circulating fetal cells (CFCs). This non-invasive method is positioned as a key future technology for prenatal testing, as it allows for the acquisition of complete fetal cells, providing more comprehensive genetic information than analysis of cell-free fetal DNA.

The company serves research and medical institutions, including providing biological technology testing services for clients like Fudan University, Zhejiang University, and Ruijin Hospital. Its business model provides a point-to-point service, delivering personalized and understandable prenatal diagnostic results to clinicians and users. Beyond prenatal diagnostics, Basetra's single-cell capture and analysis platform has applications in cancer research, stem cells, and immunology. In June 2016, the company secured $5.59 million in an Early Stage Venture Capital (Series A) funding round.

Keywords: rare cell capture, single-cell diagnostics, prenatal testing, circulating fetal cells, genomics, life sciences, medical technology, cell diagnostic technology, microfluidics, non-invasive prenatal testing, circulating tumor cells, molecular diagnostics, gene sequencing, Mycyte, biological technology services, genetic analysis